VANDA PHARMACEUTICALS INC's ticker is VNDA and the CUSIP is 921659108. A total of 134 filers reported holding VANDA PHARMACEUTICALS INC in Q2 2017. The put-call ratio across all filers is 0.32 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $23,000 | -77.5% | 2,186 | -64.7% | 0.01% | -40.0% |
| Q4 2019 | $102,000 | +32.5% | 6,197 | +6.9% | 0.02% | 0.0% |
| Q3 2019 | $77,000 | +71.1% | 5,797 | +81.2% | 0.02% | +53.8% |
| Q2 2019 | $45,000 | -81.6% | 3,199 | -75.4% | 0.01% | -60.6% |
| Q1 2019 | $244,000 | +419.1% | 13,000 | +538.8% | 0.03% | +266.7% |
| Q3 2018 | $47,000 | -79.3% | 2,035 | -82.8% | 0.01% | -82.7% |
| Q2 2018 | $227,000 | +122.5% | 11,835 | +92.9% | 0.05% | +108.0% |
| Q1 2018 | $102,000 | -12.8% | 6,135 | -20.4% | 0.02% | -7.4% |
| Q4 2017 | $117,000 | -4.1% | 7,703 | +13.2% | 0.03% | 0.0% |
| Q3 2017 | $122,000 | -62.8% | 6,803 | -66.2% | 0.03% | -43.8% |
| Q2 2017 | $328,000 | -42.2% | 20,103 | -50.4% | 0.05% | -26.2% |
| Q1 2017 | $567,000 | +141.3% | 40,503 | +175.5% | 0.06% | +116.7% |
| Q4 2016 | $235,000 | -28.4% | 14,703 | -25.4% | 0.03% | -28.6% |
| Q3 2016 | $328,000 | +375.4% | 19,700 | +217.7% | 0.04% | +320.0% |
| Q2 2016 | $69,000 | – | 6,200 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Consonance Capital Management LP | 4,658,759 | $121,733,000 | 8.95% |
| Palo Alto Investors LP | 4,155,670 | $108,588,000 | 5.78% |
| Stonepine Capital Management, LLC | 220,848 | $5,771,000 | 5.07% |
| Birchview Capital, LP | 80,000 | $2,090,000 | 1.98% |
| EAM Global Investors LLC | 75,310 | $1,968,000 | 1.08% |
| Atika Capital Management LLC | 130,000 | $3,397,000 | 1.00% |
| EAM Investors, LLC | 110,806 | $2,895,000 | 0.79% |
| UNIVERSITY OF NOTRE DAME DU LAC | 97,521 | $2,548,000 | 0.62% |
| ALGERT GLOBAL LLC | 76,204 | $1,991,000 | 0.56% |
| 361 CAPITAL LLC | 85,885 | $2,244,000 | 0.46% |